Muscle Atrophy
Conditions
Keywords
n3 PUFA
Brief summary
This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.
Detailed description
Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse. Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.
Interventions
DIETARY_SUPPLEMENTPlacebo
Organic Sunflower Oil 5000mg per day
DIETARY_SUPPLEMENTn3 PUFA-enriched fish oil
3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Sponsors
University of Guelph
McMaster University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Female * Aged 18-30 years
Exclusion criteria
* Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded * A history of neuromuscular problems or muscle and/or bone wasting diseases * Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires * Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications) * Fish allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Volume | Baseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization | Change in Muscle Volume Measured by Magnetic Resonance Imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Integrated Rates of Muscle Protein Synthesis | Before (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization | Change in Muscle Protein Synthesis |
| Skeletal Muscle Strength | Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization | Change in Skeletal Muscle Strength |
| Muscle Lipid Composition | Baseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization | Change in Muscle Lipid Composition |
Countries
Canada
Outcome results
None listed